Senseonics Holdings (NYSE: SENS) reported Q2 EPS of ($0.42), $0.39 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $2.89 million.

“In the second quarter we made progress driving increased patient and provider awareness of Eversense through a targeted direct-to-consumer digital advertising campaign and presentations of the PROMISE Study, an evaluation of our 180-day sensor, at the ADA and ATTD conferences,” said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. “As announced when we submitted this data to the FDA, we are pleased with the strength of the data from the PROMISE Study which we believe represents a top tier CGM safety and accuracy profile. Along with our commercial partner Ascensia Diabetes Care we are excited about the opportunity to offer more patients the longest lasting CGM systems.”

GUIDANCE:

The company continues to expect that global net revenue to Senseonics for the full year 2021 will be in the range of $12.0 million to $15.0 million.

For earnings history and earnings-related data on Senseonics Holdings (SENS) click here.